SCN9A Gene Insensitivity to Pain Channelopathy-Associated Genetic Test
Test Name: SCN9A Gene Insensitivity to Pain Channelopathy-Associated Genetic Test
Components: DNA Labs UAE offers this test at a price of 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Neurological Disorders
Doctor: Neurologist
Test Department: Genetics
Pre Test Information: Before undergoing the SCN9A Gene Insensitivity to Pain Channelopathy-Associated Genetic Test, it is important to provide the clinical history of the patient. A genetic counseling session will be conducted to draw a pedigree chart of family members affected with SCN9A Gene Insensitivity to Pain Channelopathy-Associated.
About SCN9A Gene Insensitivity to Pain Channelopathy-Associated Genetic Test
The SCN9A gene encodes a sodium channel called Nav1.7, which is primarily expressed in sensory neurons and plays a crucial role in transmitting pain signals. Mutations in the SCN9A gene can lead to a condition known as SCN9A gene insensitivity to pain or channelopathy-associated insensitivity to pain (CIP).
CIP is a rare genetic disorder characterized by the inability to feel physical pain. Individuals with this condition are unable to perceive pain, heat, or cold sensations, which can lead to injuries and infections going unnoticed.
CIP is usually diagnosed based on the individual’s clinical symptoms and family history of insensitivity to pain. Next-generation sequencing (NGS) is a genetic testing method that allows for the simultaneous analysis of multiple genes, including the SCN9A gene. NGS can identify specific mutations or variants in the SCN9A gene that are associated with CIP.
This type of genetic testing can help confirm a diagnosis of CIP and provide valuable information for treatment and management of the condition. It is important to note that SCN9A gene insensitivity to pain is a rare condition, and genetic testing for this disorder may not be widely available.
A genetic counselor or healthcare provider specializing in genetics can provide more information about the availability and appropriateness of NGS genetic testing for SCN9A gene insensitivity to pain.
Test Name | SCN9A Gene Insensitivity to pain channelopathy-associated Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Neurological Disorders |
Doctor | Neurologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for SCN9A Gene Insensitivity to pain, channelopathy-associated NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with SCN9A Gene Insensitivity to pain, channelopathy-associated |
Test Details |
The SCN9A gene encodes a sodium channel called Nav1.7, which is primarily expressed in sensory neurons and plays a crucial role in transmitting pain signals. Mutations in the SCN9A gene can lead to a condition known as SCN9A gene insensitivity to pain or channelopathy-associated insensitivity to pain (CIP). CIP is a rare genetic disorder characterized by the inability to feel physical pain. Individuals with this condition are unable to perceive pain, heat, or cold sensations, which can lead to injuries and infections going unnoticed. CIP is usually diagnosed based on the individual’s clinical symptoms and family history of insensitivity to pain. Next-generation sequencing (NGS) is a genetic testing method that allows for the simultaneous analysis of multiple genes, including the SCN9A gene. NGS can identify specific mutations or variants in the SCN9A gene that are associated with CIP. This type of genetic testing can help confirm a diagnosis of CIP and provide valuable information for treatment and management of the condition. It is important to note that SCN9A gene insensitivity to pain is a rare condition, and genetic testing for this disorder may not be widely available. A genetic counselor or healthcare provider specializing in genetics can provide more information about the availability and appropriateness of NGS genetic testing for SCN9A gene insensitivity to pain. |